Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
04 Octubre 2023 - 7:30AM
Artelo Biosciences, Inc. (Nasdaq:
ARTL)
, a clinical-stage pharmaceutical
company focused on modulating lipid-signaling pathways to develop
treatments for people living with cancer, pain, and neurological
conditions, today announced that H.C. Wainwright will be hosting a
virtual medical expert webinar on October 11, 2023 at 12:00 p.m.
Eastern Time to discuss the current treatment landscape for
cancer-related anorexia and cachexia. The webinar will feature
challenges and opportunities from a historical perspective and
future strategies including Artelo’s lead candidate ART27.13 which
is being developed as a supportive care therapy for people
suffering from anorexia and weight loss associated with cancer.
ARTL27.13 is currently undergoing a Phase 2a clinical trial for
this potential indication.
The webinar will be conducted as a fireside chat between
Professor Barry J. A. Laird, Institute of Genetics and Cancer at
the University of Edinburgh and Principal Investigator of Artelo’s
Cancer Appetite Recovery Study (CAReS), and Vernon Bernardino,
Managing Director and Senior Healthcare Analyst at H.C. Wainwright
& Co., LLC.
Webinar Information:
To register and access the live virtual webinar please use the
link below:Link: Registration
(ct.events)Date: October 11,
2023Time: 12:00 p.m. Eastern Time
About Professor Barry J.A.
LairdProfessor Barry Laird is the
coordinating investigator for the Cancer Appetite Recovery Study
(CAReS) researching cancer anorexia. He is an academic clinician
specializing in palliative medicine at the University of Edinburgh
and is a medical expert in cancer cachexia and anorexia research.
Clinically, Professor Laird holds consultant positions in
Palliative Medicine at the Edinburgh Cancer Centre and St Columba’s
Hospice. He is passionate about improving symptoms in people with
life-limiting illnesses. The main focus of his research is
understanding how the tumor-host interaction in cancer is
implicated in cancer cachexia. Professor Laird leads a research
program examining the systemic inflammatory response in cachexia,
symptom genesis and prognosis in cancer. He has published over 70
papers and is the lead investigator of clinical trials in
symptomatology and treatment.
About ART27.13ART27.13 is a highly potent,
peripherally restricted synthetic, dual G-Protein-Coupled Receptor
agonist believed to target the cannabinoid receptors CB1 and
CB2, which has the potential to increase appetite and food intake.
Originally developed by AstraZeneca plc, ART27.13 has been
evaluated in five Phase 1 clinical studies including over 200
subjects where it has demonstrated a statistically
significant and dose-dependent increase in body weight in
healthy subjects. Importantly, the changes in body weight were not
associated with fluid retention and the distribution of the drug
enables systemic metabolic effects while minimizing central nervous
system-mediated toxicity. Artelo is advancing ART27.13 as a
supportive care therapy for cancer patients suffering from anorexia
and weight loss, where the current annual global market is
estimated to be valued in excess of $2 billion.
About CAReSThe Cancer Appetite Recovery Study
(CAReS) is a Phase 1b/2a randomized, placebo-controlled trial of
the Company’s lead clinical program, ART27.13, in patients with
cancer anorexia and weight loss. Anorexia, or the lack or loss of
appetite, may result from the cancer and/or its treatment with
radiation or chemotherapy. It is common for patients with cancer to
lose weight. Anorexia and the resulting weight loss can affect a
patient’s health, often weakening their immune system and causing
discomfort and dehydration. It can also be associated with
cachexia, or muscle wasting. A weight loss of more than 5% can
predict a poor outcome for cancer patients and a lower response to
chemotherapy. The Phase 1b portion of the CAReS study is designed
to determine the most effective and safest dose of ART27.13 for
dosing in the Phase 2a stage. The Phase 2a portion of the CAReS
study is designed to determine estimates of activity of ART27.13 in
terms of lean body mass, weight gain, and improvement of anorexia.
(ISRCTN registry: https://www.isrctn.com/ISRCTN15607817)
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De May 2023 a May 2024